CDKN2A and oropharyngeal carcinoma: Notably, patients with p16+ oropharyngeal carcinoma demonstrated better three-year PFS and overall survival compared to those with p16- oropharyngeal carcinoma, while tumor EGFR expression did not significantly affect the outcome (48).